<p>Cullinan Therapeutics, Inc.（纳斯达克代码：CGEM - 获取免费报告）的股票在周一交易中下跌了 9.5%。该股最低交易价为 10.94 美元，最后交易价为 10.79 美元。在午间交易中，约有 766,760 股易手，较日均交易量 642,363 股增加了 19%。该股此前收盘价为 11.92 美元。</p>
<p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>多位股票分析师最近对 CGEM 股票发表了评论。HC Wainwright 将 Cullinan Therapeutics 的目标价从 24.00 美元上调至 26.00 美元，并在 11 月 20 日的研究报告中给予该股 “买入” 评级。Wall Street Zen 在 11 月 22 日的研究报告中将 Cullinan Therapeutics 的评级从 “卖出” 上调至 “持有”。Wedbush 在 12 月 9 日的研究报告中将 Cullinan Therapeutics 的目标价从 25.00 美元上调至 34.00 美元，并给予该股 “跑赢大盘” 评级。摩根士丹利在 8 月 18 日的报告中将 Cullinan Therapeutics 的目标价从 35.00 美元下调至 28.00 美元，并对该股设定 “增持” 评级。最后，Zacks Research 在 9 月 16 日的报告中将 Cullinan Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。六位分析师给予该股 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “适度买入”，平均目标价为 28.29 美元。</p>
<p><strong>查看我们最新的 Cullinan Therapeutics 股票报告</strong></p>
<h2>Cullinan Therapeutics 股票表现</h2>
<p>该股市值为 6.3925 亿美元，市盈率为-3.27，贝塔值为-0.11。该公司的 50 日移动平均线为 8.99 美元，200 日移动平均线为 8.06 美元。</p>
<p>Cullinan Therapeutics（纳斯达克代码：CGEM - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益为-0.77 美元，超出分析师共识预期的-0.95 美元，超出幅度为 0.18 美元。卖方分析师预计 Cullinan Therapeutics, Inc.在当前财年将发布-3.04 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在其他消息中，主要股东 Lynx1 Capital Management Lp 在 10 月 9 日的交易中购买了 626,043 股该公司的股票。该股的平均购买价格为每股 6.70 美元，总价值为 4,194,488.10 美元。收购完成后，该内部人士持有 8,271,786 股该公司的股票，价值约为 55,420,966.20 美元。这笔交易代表其持股比例增加了 8.19%。该交易已在 SEC 的法律文件中披露，具体信息可在此链接查看。此外，内部人士 Jennifer Michaelson 在 11 月 24 日的交易中出售了 4,000 股该股票。该股的平均出售价格为 12.30 美元，总交易额为 49,200.00 美元。出售完成后，该内部人士直接持有 138,004 股该公司的股票，价值约为 1,697,449.20 美元。这笔交易代表其持股比例减少了 2.82%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士共购买了价值 13,325,286 美元的 1,874,057 股公司股票。公司内部人士持有该公司 6.07% 的股份。</p>
<h2>机构投资者对 Cullinan Therapeutics 的看法</h2>
<p>多家机构投资者最近调整了对该公司的持股。Brooklyn Investment Group 在第一季度新建了约 34,000 美元的 Cullinan Therapeutics 头寸。Tower Research Capital LLC TRC 在第二季度将其在 Cullinan Therapeutics 的持股增加了 44.6%。Tower Research Capital LLC TRC 目前持有 8,182 股该公司的股票，价值 62,000 美元，此前在上一季度又购买了 2,523 股。SG Americas Securities LLC 在第三季度购买了约 62,000 美元的 Cullinan Therapeutics 新头寸。Y Intercept Hong Kong Ltd 在第二季度购买了约 84,000 美元的 Cullinan Therapeutics 新头寸。最后，Inscription Capital LLC 在第三季度收购了价值 67,000 美元的 Cullinan Therapeutics 新股份。86.31% 的股票由机构投资者和对冲基金持有。</p>
<h2>Cullinan Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cullinan Therapeutics, Inc.是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种正在进行 I 期临床试验的单克隆抗体，用于治疗实体肿瘤。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，正在进行 I 期临床试验，用于治疗急性髓性白血病或骨髓增生异常综合症；CLN-418，这是一种人源化双特异性免疫激活剂，正在进行 I 期临床试验，用于治疗多种实体肿瘤；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Cullinan Therapeutics</li>
<li>百分比涨幅对投资者的意义及其为何不能说明全部情况</li>
<li>Nutanix 是否是 2025 年最佳反弹交易？设置表明是</li>
<li>内部交易 - 你需要知道的事项</li>
<li>Vertiv 回调：忽略噪音，购买数据</li>
<li>如何利用高贝塔股票最大化投资利润</li>
<li>内部人士购买天然气股票：2 只值得关注的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
<p>在你考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cullinan Therapeutics 并不在名单上。</p>
<p>虽然 Cullinan Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGEM

<p>Cullinan Therapeutics（纳斯达克股票代码：CGEM）的股价下跌了 9.5%，至 10.79 美元，交易量有所增加。分析师的评级不一，有些分析师上调了目标价格。该公司报告的季度收益好于预期。内部交易活动包括大量的买入和卖出。机构投资者也调整了他们的持股。Cullinan 专注于开发肿瘤治疗药物，目前有多个项目处于临床试验阶段</p>

<p>Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) dropped 9.5% during trading on Monday . The stock traded as low as $10.94 and last traded at $10.79. Approximately 766,760 shares changed hands during mid-day trading, an increase of 19% from the average daily volume of 642,363 shares. The stock had previously closed at $11.92.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc.（纳斯达克代码：CGEM - 获取免费报告）的股票在周一交易中下跌了 9.5%。该股最低交易价为 10.94 美元，最后交易价为 10.79 美元。在午间交易中，约有 766,760 股易手，较日均交易量 642,363 股增加了 19%。该股此前收盘价为 11.92 美元。</p>
</div><p>Get <strong>Cullinan Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently commented on CGEM shares. HC Wainwright raised their target price on shares of Cullinan Therapeutics from $24.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, November 20th. Wall Street Zen raised shares of Cullinan Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. Wedbush boosted their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, December 9th. Morgan Stanley dropped their price objective on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, August 18th. Finally, Zacks Research upgraded shares of Cullinan Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, September 16th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.29.</p>
<div class="lb-trans"><p>多位股票分析师最近对 CGEM 股票发表了评论。HC Wainwright 将 Cullinan Therapeutics 的目标价从 24.00 美元上调至 26.00 美元，并在 11 月 20 日的研究报告中给予该股 “买入” 评级。Wall Street Zen 在 11 月 22 日的研究报告中将 Cullinan Therapeutics 的评级从 “卖出” 上调至 “持有”。Wedbush 在 12 月 9 日的研究报告中将 Cullinan Therapeutics 的目标价从 25.00 美元上调至 34.00 美元，并给予该股 “跑赢大盘” 评级。摩根士丹利在 8 月 18 日的报告中将 Cullinan Therapeutics 的目标价从 35.00 美元下调至 28.00 美元，并对该股设定 “增持” 评级。最后，Zacks Research 在 9 月 16 日的报告中将 Cullinan Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。六位分析师给予该股 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “适度买入”，平均目标价为 28.29 美元。</p>
</div><p><strong>View Our Latest Stock Report on Cullinan Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Cullinan Therapeutics 股票报告</strong></p>
</div><h2>Cullinan Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 股票表现</h2>
</div><p>The stock has a market cap of $639.25 million, a price-to-earnings ratio of -3.27 and a beta of -0.11. The business's 50 day moving average is $8.99 and its 200-day moving average is $8.06.</p>
<div class="lb-trans"><p>该股市值为 6.3925 亿美元，市盈率为-3.27，贝塔值为-0.11。该公司的 50 日移动平均线为 8.99 美元，200 日移动平均线为 8.06 美元。</p>
</div><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18. Sell-side analysts anticipate that Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cullinan Therapeutics（纳斯达克代码：CGEM - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益为-0.77 美元，超出分析师共识预期的-0.95 美元，超出幅度为 0.18 美元。卖方分析师预计 Cullinan Therapeutics, Inc.在当前财年将发布-3.04 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, major shareholder Lynx1 Capital Management Lp acquired 626,043 shares of the company's stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average price of $6.70 per share, with a total value of $4,194,488.10. Following the completion of the acquisition, the insider owned 8,271,786 shares of the company's stock, valued at $55,420,966.20. This trade represents a 8.19% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jennifer Michaelson sold 4,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $12.30, for a total transaction of $49,200.00. Following the completion of the sale, the insider directly owned 138,004 shares of the company's stock, valued at approximately $1,697,449.20. This trade represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders acquired a total of 1,874,057 shares of company stock worth $13,325,286 over the last three months. Corporate insiders own 6.07% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，主要股东 Lynx1 Capital Management Lp 在 10 月 9 日的交易中购买了 626,043 股该公司的股票。该股的平均购买价格为每股 6.70 美元，总价值为 4,194,488.10 美元。收购完成后，该内部人士持有 8,271,786 股该公司的股票，价值约为 55,420,966.20 美元。这笔交易代表其持股比例增加了 8.19%。该交易已在 SEC 的法律文件中披露，具体信息可在此链接查看。此外，内部人士 Jennifer Michaelson 在 11 月 24 日的交易中出售了 4,000 股该股票。该股的平均出售价格为 12.30 美元，总交易额为 49,200.00 美元。出售完成后，该内部人士直接持有 138,004 股该公司的股票，价值约为 1,697,449.20 美元。这笔交易代表其持股比例减少了 2.82%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士共购买了价值 13,325,286 美元的 1,874,057 股公司股票。公司内部人士持有该公司 6.07% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Cullinan Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Cullinan Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Brooklyn Investment Group acquired a new position in Cullinan Therapeutics in the 1st quarter valued at about $34,000. Tower Research Capital LLC TRC raised its stake in Cullinan Therapeutics by 44.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock valued at $62,000 after buying an additional 2,523 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Cullinan Therapeutics in the 3rd quarter valued at about $62,000. Y Intercept Hong Kong Ltd purchased a new position in Cullinan Therapeutics in the second quarter valued at approximately $84,000. Finally, Inscription Capital LLC acquired a new stake in Cullinan Therapeutics during the 3rd quarter worth $67,000. 86.31% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>多家机构投资者最近调整了对该公司的持股。Brooklyn Investment Group 在第一季度新建了约 34,000 美元的 Cullinan Therapeutics 头寸。Tower Research Capital LLC TRC 在第二季度将其在 Cullinan Therapeutics 的持股增加了 44.6%。Tower Research Capital LLC TRC 目前持有 8,182 股该公司的股票，价值 62,000 美元，此前在上一季度又购买了 2,523 股。SG Americas Securities LLC 在第三季度购买了约 62,000 美元的 Cullinan Therapeutics 新头寸。Y Intercept Hong Kong Ltd 在第二季度购买了约 84,000 美元的 Cullinan Therapeutics 新头寸。最后，Inscription Capital LLC 在第三季度收购了价值 67,000 美元的 Cullinan Therapeutics 新股份。86.31% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Cullinan Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc.是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种正在进行 I 期临床试验的单克隆抗体，用于治疗实体肿瘤。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，正在进行 I 期临床试验，用于治疗急性髓性白血病或骨髓增生异常综合症；CLN-418，这是一种人源化双特异性免疫激活剂，正在进行 I 期临床试验，用于治疗多种实体肿瘤；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cullinan Therapeutics</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>Is Nutanix the Best Comeback Trade Left in 2025? The Setup Says Yes</li>
<li>Insider Trading - What You Need to Know</li>
<li>The Vertiv Pullback: Ignore the Noise, Buy the Data</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Cullinan Therapeutics</li>
<li>百分比涨幅对投资者的意义及其为何不能说明全部情况</li>
<li>Nutanix 是否是 2025 年最佳反弹交易？设置表明是</li>
<li>内部交易 - 你需要知道的事项</li>
<li>Vertiv 回调：忽略噪音，购买数据</li>
<li>如何利用高贝塔股票最大化投资利润</li>
<li>内部人士购买天然气股票：2 只值得关注的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
</div><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cullinan Therapeutics 并不在名单上。</p>
</div><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cullinan Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cullinan Therapeutics（纳斯达克代码：CGEM）股价下跌 9.5% - 接下来会如何发展？